Evidence map›Paper›PMID 29263660›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2017

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD.

Jieun Kang, Ki Tae Kim, Ji-Hyun Lee, Eun Kyung Kim, Tae-Hyung Kim, Kwang Ha Yoo, Jae Seung Lee, Woo Jin Kim, Ju Han Kim, Yeon-Mok Oh

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Dysanapsis and the Spirometric Response to Inhaled Bronchodilators.American journal of respiratory and critical care medicine · 2021
    Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jieun Kang *Department of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
Ki Tae Kim *Seoul National University Biomedical Informatics and Systems Biomedical Informatics Research Center, Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul.
Ji-Hyun LeeDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam.
Eun Kyung KimDepartment of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam.
Tae-Hyung KimDivision of Pulmonology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri.
Kwang Ha YooDepartment of Internal Medicine, Konkuk University Hospital, Konkuk University School of Medicine, Seoul.
Jae Seung LeeDepartment of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.
Woo Jin KimDepartment of Internal Medicine and Environmental Health Center, Kangwon National University Hospital, School of Medicine, Kangwon National University, Chuncheon, South Korea.
Ju Han KimSeoul National University Biomedical Informatics and Systems Biomedical Informatics Research Center, Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul.
Yeon-Mok OhDepartment of Pulmonology and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is currently no measure to predict a treatability of long-acting β-2 agonist (LABA) or long-acting muscarinic antagonist (LAMA) in patients with chronic obstructive pulmonary disease (COPD). We aimed to build prediction models for the treatment response to these bronchodilators, in order to determine the most responsive medication for patients with COPD.

methodsWe performed a prospective open-label crossover study, in which each long-acting bronchodilator was given in a random order to 65 patients with stable COPD for 4 weeks, with a 4-week washout period in between. We analyzed 14 baseline clinical traits, expression profiles of 31,426 gene transcripts, and damaged-gene scores of 6,464 genes acquired from leukocytes. The gene expression profiles were measured by RNA microarray and the damaged-gene scores were obtained after DNA exome sequencing. Linear regression analyses were performed to build prediction models after using factor and correlation analyses.

resultsUsing a prediction model for a LABA, traits found associated with the treatment response were post-bronchodilator forced expiratory volume in 1 second, bronchodilator reversibility (BDR) to salbutamol, expression of three genes (

conclusionAdding the expressions of genes and damaged-gene scores to the clinical traits may improve the predictability of treatment response to long-acting bronchodilators.

Indexed as

Oligonucleotide Array Sequence AnalysisQuantitative Trait, HeritableTranscriptomeAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsClinical Decision-MakingCross-Over StudiesFemaleForced Expiratory VolumeGene Expression ProfilingHumansIndansLungMaleMiddle AgedAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsindacaterolIndansMuscarinic AntagonistsQuinolonesTiotropium Bromidechronic obstructive lung diseaseinhalerslong-acting muscarinic antagonistlong-acting β-2 agonist

Identifiers

PMID29263660
PMCPMC5732547

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.